HRTX vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HRTX presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of positive technical momentum (0/100). While the company maintains strong gross margins (72.64%) and a healthy current ratio (2.48), these are overshadowed by an extreme Debt/Equity ratio of 9.81 and a catastrophic 5-year price decline of 94.8%. There is a severe disconnect between the 'Strong Buy' analyst consensus with a $4.33 target and the actual market performance and fundamental leverage.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HRTX vs MRK: Head-to-Head Comparison
This page compares Heron Therapeutics, Inc. (HRTX) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.